|Blinatumomab, a Bispecific T-cell Engager (BiTE®) for CD-19 Targeted Cancer Immunotherapy: Clinical Pharmacology and Its Implications|
M Zhu, B Wu, C Brandl, J Johnson, A Wolf, A Chow, S Doshi
Clinical pharmacokinetics 55, 1271-1288, 2016
|Population pharmacokinetic meta-analysis of denosumab in healthy subjects and postmenopausal women with osteopenia or osteoporosis|
L Sutjandra, RD Rodriguez, S Doshi, M Ma, MC Peterson, GR Jang, ...
Clinical pharmacokinetics 50, 793-807, 2011
|Population pharmacokinetic analysis of denosumab in patients with bone metastases from solid tumours|
L Gibiansky, L Sutjandra, S Doshi, J Zheng, W Sohn, MC Peterson, ...
Clinical pharmacokinetics 51, 247-260, 2012
|Pharmacodynamics-mediated drug disposition (PDMDD) and precursor pool lifespan model for single dose of romiplostim in healthy subjects|
YMC Wang, W Krzyzanski, S Doshi, JJ Xiao, JJ Pérez-Ruixo, AT Chow
The AAPS journal 12, 729-740, 2010
|Population pharmacokinetics of rilotumumab, a fully human monoclonal antibody against hepatocyte growth factor, in cancer patients|
M Zhu, S Doshi, PO Gisleskog, KS Oliner, JJP Ruixo, E Loh, Y Zhang
Journal of Pharmaceutical Sciences 103 (1), 328-336, 2014
|Rilotumumab exposure–response relationship in patients with advanced or metastatic gastric cancer|
S Doshi, PO Gisleskog, Y Zhang, M Zhu, KS Oliner, E Loh, JJP Ruixo
Clinical Cancer Research 21 (11), 2453-2461, 2015
|Investigation of the effects of altered receptor binding activity on the clearance of erythropoiesis-stimulating proteins: nonerythropoietin receptor-mediated pathways may play …|
B Agoram, K Aoki, S Doshi, C Gegg, G Jang, G Molineux, L Narhi, S Elliott
Journal of pharmaceutical sciences 98 (6), 2198-2211, 2009
|Exposure-response analysis of rilotumumab in gastric cancer: the role of tumour MET expression|
M Zhu, R Tang, S Doshi, KS Oliner, S Dubey, Y Jiang, RC Donehower, ...
British journal of cancer 112 (3), 429-437, 2015
|Impact of target‐mediated elimination on the dose and regimen of evolocumab, a human monoclonal antibody against proprotein convertase subtilisin/kexin type 9 (PCSK9)|
JP Gibbs, S Doshi, M Kuchimanchi, A Grover, MG Emery, MG Dodds, ...
The Journal of Clinical Pharmacology 57 (5), 616-626, 2017
|Tumor penetration and epidermal growth factor receptor saturation by panitumumab correlate with antitumor activity in a preclinical model of human cancer|
DJ Freeman, K McDorman, S Ogbagabriel, C Kozlosky, BB Yang, S Doshi, ...
Molecular Cancer 11, 1-11, 2012
|Pharmacodynamics of romiplostim alone and in combination with pegfilgrastim on acute radiation-induced thrombocytopenia and neutropenia in non-human primates|
K Wong, PY Chang, M Fielden, AM Downey, D Bunin, J Bakke, ...
International journal of radiation biology 96 (1), 155-166, 2020
|Denosumab dose selection for patients with bone metastases from solid tumors|
S Doshi, L Sutjandra, J Zheng, W Sohn, M Peterson, G Jang, AT Chow, ...
Clinical Cancer Research 18 (9), 2648-2657, 2012
|Blinatumomab pharmacodynamics and exposure–response relationships in relapsed/refractory acute lymphoblastic leukemia|
M Zhu, A Kratzer, J Johnson, C Holland, C Brandl, I Singh, A Wolf, ...
The Journal of Clinical Pharmacology 58 (2), 168-179, 2018
|Exposure‐response modeling of darbepoetin alfa in anemic patients with chronic kidney disease not receiving dialysis|
S Doshi, A Chow, JJP Ruixo
The Journal of Clinical Pharmacology 50 (S9), 75S-90S, 2010
|Clinical pharmacokinetics and pharmacodynamics of erythropoiesis-stimulating agents|
S Doshi, W Krzyzanski, S Yue, S Elliott, A Chow, JJ Pérez-Ruixo
Clinical pharmacokinetics 52, 1063-1083, 2013
|Comparison of LDL-C reduction using different evolocumab doses and intervals: biological insights and treatment implications|
SM Wasserman, MS Sabatine, MJ Koren, RP Giugliano, JC Legg, ...
Journal of Cardiovascular Pharmacology and Therapeutics 23 (5), 423-432, 2018
|Development of romiplostim for treatment of primary immune thrombocytopenia from a pharmacokinetic and pharmacodynamic perspective|
BB Yang, S Doshi, K Arkam, J Franklin, AT Chow
Clinical Pharmacokinetics 55, 1045-1058, 2016
|Population pharmacokinetics of blinatumomab in pediatric and adult patients with hematological malignancies|
JD Clements, M Zhu, M Kuchimanchi, B Terminello, S Doshi
Clinical pharmacokinetics 59, 463-474, 2020
|Population pharmacokinetics and exposure–response relationship of carfilzomib in patients with multiple myeloma|
Y Ou, S Doshi, A Nguyen, F Jonsson, S Aggarwal, K Rajangam, ...
The Journal of Clinical Pharmacology 57 (5), 663-677, 2017
|Pharmacokinetics and pharmacodynamics of rilotumumab: a decade of experience in preclinical and clinical cancer research|
Y Zhang, S Doshi, M Zhu
British journal of clinical pharmacology 80 (5), 957-964, 2015